The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...

Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan TOKYO, Mar 5, 2025 - (J ...

President Donald Trump's nominee for NIH director, Dr Jay Bhattacharya, fielded intense questioning on vaccines and cuts to ...